The C-terminal HSP90 inhibitor NCT-58 kills trastuzumab-resistant breast cancer stem-like cells
$ 5.00 · 4.8 (291) · In stock
Cancers, Free Full-Text
Following the design path of isoform-selective Hsp90 inhibitors: Small differences, great opportunities - ScienceDirect
PDF) A novel HSP90 inhibitor SL-145 suppresses metastatic triple-negative breast cancer without triggering the heat shock response
β-Escin overcomes trastuzumab resistance in HER2-positive breast cancer by targeting cancer stem-like features, Cancer Cell International
Following the design path of isoform-selective Hsp90 inhibitors: Small differences, great opportunities - ScienceDirect
Biomolecules, Free Full-Text
An ErbB-2 molecule unable to bind Hsp90 shows enhanced activity. (A)
NCT-58, HSP90 C-terminal Inhibitor
β-Escin overcomes trastuzumab resistance in HER2-positive breast cancer by targeting cancer stem-like features, Cancer Cell International
PDF) A novel HSP90 inhibitor SL-145 suppresses metastatic triple-negative breast cancer without triggering the heat shock response
Recent advances toward the development of Hsp90 C-terminal inhibitors - ScienceDirect
β-Escin overcomes trastuzumab resistance in HER2-positive breast cancer by targeting cancer stem-like features, Cancer Cell International
PDF) A novel HSP90 inhibitor targeting the C-terminal domain attenuates trastuzumab resistance in HER2-positive breast cancer
Hsp90 Inhibition Results in Glucocorticoid Receptor Degradation in Association with Increased Sensitivity to Paclitaxel in Triple-Negative Breast Cancer
Cancers, Free Full-Text